Scientists at the University of Cambridge have built a miniature, living model of the human brain and spinal cord that challenges one of neuroscience’s hardest limits: the idea that damage to central nervous system connections is permanent. Using the model, the team showed that the lost ability of nerve fibers to regrow can be switched back on, opening a long-term avenue toward treating conditions such as spinal cord injury, motor neurone disease, and multiple sclerosis.
The findings, published May 28 in Cell Reports, do not amount to a treatment. They come from organoids grown in a dish, not from patients. But they reframe a problem that has stood in the way of repair for decades, and they identify a specific biological mechanism that future therapies might target.
Building A Connected Nervous System In A Dish
The human brain and spinal cord are distinct tissues joined by axons, the long nerve fibers that carry movement signals. To recreate that architecture, the researchers grew brain and spinal cord organoids from human stem cells and deliberately kept them apart. Over time, nerve fibers from the brain tissue reached across the gap, connected to the spinal cord, and formed a working circuit capable of triggering tiny muscle clusters to contract.
The work builds on the lab’s 2021 development of pea-sized “mini brains,” which the team previously used to study molecular faults in motor neurone disease. The new model extends that approach into a connected system, allowing the researchers to watch how the human brain-spinal cord link forms and, crucially, when it loses the capacity to repair itself.
That distinction matters because most knowledge of nerve regeneration comes from rodents. As the project’s senior author, Dr András Lakatos of the Department of Clinical Neurosciences, noted, rodent neurons behave differently from human ones, and organoid models help bridge the gap between animal studies and what clinicians actually see in patients. The team also framed the work as a contribution to reducing reliance on animals in research.
A Developmental “Switch” That Shuts Down Repair
By growing the system for more than a year, the researchers pinpointed a turning point. Up to around day 150, corresponding to the mid-trimester of pregnancy, axons could regrow after injury. After that, their capacity to regenerate dropped sharply.
George Gibbons, the study’s first author, described the pattern plainly: neurons from less mature organoids regrew long fibers after injury, while those from more mature organoids showed a steep decline in that ability. In his words, poor regeneration appears to be built into human neurons as they mature within the central nervous system.
Analyzing gene activity in the neurons linking brain and spinal cord, the team identified a network of genes acting as a switch that restricts axon growth as neurons mature and form connections. Blocking key regulators of that network reactivated the cells’ ability to grow new fibers, a result that points to the mechanism rather than merely the symptom.
An Existing Drug Offered A Clue
To test whether the switch could be targeted with available compounds, the researchers scanned a drug database for candidates acting on the relevant genes. They identified lynestrenol, a hormone drug already licensed for managing certain menstrual disorders and as a contraceptive. Applied to damaged neurons in the model, it significantly boosted axon regrowth.
Lakatos was careful about what that does and does not mean. Lynestrenol itself may not be the answer to spinal cord repair, he said, but it demonstrates that directly targeting human neurons to regenerate their axons should be possible in principle. He added that the team still needs to show the approach can re-establish the correct connections between brain and spinal cord cells, while expressing hope that conditions once considered untreatable might one day be addressed.
Why The Result Carries Weight
Damage to the brain and spinal cord rarely heals because the nerve fibers carrying movement signals do not grow back, which is why paralysis is usually permanent. Scar tissue and inflammation contribute to that failure, but the Cambridge work focuses on a neuron-specific cause, supported by evidence that fibers from less mature neurons can grow through the hostile environment of an injury site.
The research was funded by the UK Research and Innovation Medical Research Council and the charity Spinal Research. Its chief executive, Louisa McGinn, tied the result to the roughly 15 million people worldwide living with spinal cord injury, describing the next five years as an opportunity to move breakthrough therapies closer to clinical reality.
For now, the model’s value lies in what it reveals: that the block on regeneration is installed during development and, at least in a dish, can be lifted afterward. Translating that into a therapy will require years of further work, but the study narrows a question that has long resisted answers.
Disclaimer: This article is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. The research described involves a laboratory organoid model and has not been tested or approved as a treatment in humans. Lynestrenol is not approved or proven for nerve regeneration or spinal cord repair, and no findings here should be used to guide medical decisions. Anyone with a health condition should consult a qualified healthcare professional, and no one should start, stop, or alter any medication based on this article.
